Clinical trial NCT03245645: FODMAP Reintroduction in Irritable Bowel Syndrome
Official title: FODMAP Reintroduction in Irritable Bowel Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Irritable Bowel Syndrome With Diarrhea
Irritable Bowel Syndrome With Mixed Bowel Habits
Keywords: FODMAP
IBS
Diet
Re-introduction
Fructose
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2017-08-10
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the amount and timing of when certain Fermentable Oligo-Di-Monosaccharides and Polyols (FODMAPs), specifically fructose, can be safely reintroduced into the diet of Irritable Bowel Syndrome (IBS) patients that have successfully completed a low-FODMAP elimination diet. The FODMAP diet is an effective treatment for IBS; however it is unclear how patients can successfully reintroduce and liberalize fructose into their diet. The low FODMAP diet is thought to reduce IBS symptoms by decreasing water content and gas production in the bowel and also possibly by altering gut bacteria. Although use of the FODMAP elimination diet can initially successfully treat IBS symptoms for up to 50-75% of patients, the reintroduction diet is difficult for patients to complete and maintain for long periods of time because current methods for reintroduction of FODMAPs are imprecise leading to frequent recurrent symptoms. As a result, patients often continue the low FODMAP elimination diet for additional months because they have difficulties knowing how to add back FODMAPs into their diet. There are no studies to date to help guide patients with FODMAP reintroduction.

Detailed description: Research supports clinical experience that ingestion of food often triggers the emergence or exacerbation of symptoms in the majority of patients with irritable bowel syndrome (IBS). While IBS remains primarily a symptom driven entity, our understanding of its pathophysiology is evolving. However, comparatively little research has focused on the specific role of certain foods and how they prompt the development of IBS symptoms.

Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (fermentable oligosaccharides, disacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. There are no human gut specific fructose transporters. Rather glucose transporters are used (GLUT 2,5) leading some to hypothesize that over ingestion of these agents may trigger some of the enteric complaints of patients with IBS. The literature on fructose malabsorption gives varying threshold amounts: from 15 to 50 grams in healthy controls, and from 5 to 50 grams in IBS patients/known malabsorbers (Barrett, 2007; Rao, 2007; Frieling, 2011). Average daily fructose consumption in the American diet is approximately 34 grams, with a range of 15 to 54 grams, which falls well within the threshold levels (Frieling, 2011). FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.

There are risks to prolonged use of a low FODMAPs diet. A study from 2012 suggested that continued restriction of FODMAPS (longer than 4 weeks) can lead to reduction of luminal bifidobacteria in patients with IBS. Bifidobacteria mainly inhabit the large intestine where they produce short chain fatty acids (SCFA) as byproducts, including butyrate, shown to be important for colorectal cancer prevention and limit enteropathogenic colonization. Furthermore the diet is very restrictive and difficult for patients to maintain over time.

However, important clinical questions include when FODMAPS can be safely reintroduced into the diet, how quickly this can be accomplished, and what is a daily threshold of intake that is acceptable for IBS patients who respond or do not respond to a low FODMAPs diet. There are no evidence based answers to these questions, and it is in this setting that we propose our current project.

Eligibility criteria: Inclusion Criteria:

* Adults (18+ years or older) with a diagnosis of IBS-D or IBS-M based on Rome IV criteria
* Diarrhea must occur 2 or more days per week
* Patients on current pharmacological therapy for their gastrointestinal complaints can enroll in the study as long as they have been on a stable dose for at least 30 days.

Exclusion Criteria:

* Significant comorbidities that are associated with GI symptoms (e.g. diabetes, scleroderma, SLE), history of GI surgery excluding appendectomy, or prior organic GI illness
* Antibiotics taken in the past 2 months
* Current disordered eating patterns (diagnosed eating disorder; as per verbal ESP questionnaire)
* Current history of greater than moderate alcohol intake (more than 1 drink per day for women, more than 2 drinks per day for men, binge drinking behavior of 5+ drinks in a single session once per week)
* Cannot have had a cholecystectomy in the past 6 months prior to enrollment

Primary outcomes:
measure: Adequate relief of IBS symptoms in past 7 days
timeFrame: Baseline, 4 weeks (post-elimination diet)
measure: Highest amount of grams of sugar in solutions that do not significantly increase IBS symptoms
timeFrame: Daily, during weeks 5-7 (reintroduction phase)
Secondary outcomes:
measure: Change in IBS-symptom severity scale
timeFrame: Baseline, 4 weeks (post-elimination diet), 7 weeks (post-reintroduction phase)
measure: Change in Visceral Sensitivity Index (VSI)
timeFrame: Baseline, 4 weeks (post-elimination diet), 7 weeks (post-reintroduction phase)
measure: Change in Personal Health Questionnaire (PHQ-15)
timeFrame: Baseline, 4 weeks (post-elimination diet), 7 weeks (post-reintroduction phase)
measure: Change in abdominal pain severity
timeFrame: Baseline, 4 weeks (post-elimination diet), 7 weeks (post-reintroduction phase)
measure: Change in overall severity of gastrointestinal symptoms
timeFrame: Baseline, 4 weeks (post-elimination diet), 7 weeks (post-reintroduction phase)
measure: Change in severity of the sensation of bloating, abdominal fullness or visible distension
timeFrame: Baseline, 4 weeks (post-elimination diet), 7 weeks (post-reintroduction phase)
measure: Change in intestinal microbiota
timeFrame: Baseline, 4 weeks (post-elimination diet)
measure: Change in visceral sensitivity index score
timeFrame: Baseline, 4 weeks (post-elimination diet), 7 weeks (post-reintroduction phase)
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Lin Chang, MD
role: PRINCIPAL_INVESTIGATOR
References: